Parallel Advisors, LLC Adaptimmune Therapeutics PLC Transaction History

Parallel Advisors, LLC

  • $4.87 Billion
  • Q2 2025

A detailed history of Parallel Advisors, LLC transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Parallel Advisors, LLC holds 250 shares of ADAP stock, worth $12. This represents 0.0% of its overall portfolio holdings.

Number of Shares
250
Previous 250 -0.0%
Holding current value
$12
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 10, 2025
SELL
$0.54 - $0.95 $3,743 - $6,586
-6,933 Reduced 96.52%
250 $0
Q3 2024

Nov 13, 2024
BUY
$0.92 - $1.39 $6,378 - $9,636
6,933 Added 2773.2%
7,183 $6,000
Q2 2024

Aug 08, 2024
BUY
$0.83 - $1.47 $207 - $367
250 New
250 $0
Q2 2022

Aug 01, 2022
SELL
$1.33 - $2.28 $2,464 - $4,224
-1,853 Closed
0 $0
Q1 2022

Apr 28, 2022
BUY
$1.73 - $4.06 $1,800 - $4,226
1,041 Added 128.2%
1,853 $4,000
Q3 2021

Nov 02, 2021
BUY
$3.44 - $6.37 $333 - $617
97 Added 13.57%
812 $4,000
Q1 2021

Apr 23, 2021
SELL
$4.9 - $6.83 $931 - $1,297
-190 Reduced 20.99%
715 $4,000
Q4 2020

Feb 02, 2021
BUY
$4.0 - $9.2 $760 - $1,747
190 Added 26.57%
905 $5,000
Q2 2020

Jul 16, 2020
SELL
$2.58 - $12.1 $959 - $4,501
-372 Reduced 34.22%
715 $7,000
Q1 2020

Apr 27, 2020
BUY
$1.2 - $4.52 $1,304 - $4,913
1,087 New
1,087 $2,000
Q4 2019

Jan 30, 2020
SELL
$0.72 - $1.43 $0 - $0
0 Closed
0 $0
Q3 2019

Nov 01, 2019
SELL
$1.43 - $3.81 $449 - $1,196
-314 Closed
0 $0
Q4 2018

Feb 05, 2019
BUY
$3.76 - $14.16 $1,180 - $4,446
314 New
314 $1,000

Others Institutions Holding ADAP

# of Institutions
70
Shares Held
116M
Call Options Held
10.3K
Put Options Held
0
View Full List

About Adaptimmune Therapeutics PLC

ADAP Quotes by TradingView
  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $8.17M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email